Annual Report 2020

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

June 2, 2021Promore Pharma publishes prospectus
May 27, 2021Promore Pharma informs about the last day of trading to receive subscription rights
May 27, 2021Interim report January – March 2021
May 27, 2021Report from an extra General Meeting of Promore Pharma AB held on 27 May 2021
May 27, 2021Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

More Press Releases

Interim report January – March 2021

Promore Pharma AB (publ) published its Q1 report for 2021 on 27 May 2021.

Read the report

Calendar

August 24, 2021Interim report January – July 2021
November 23, 2021Interim report January – September 2021

More Events

Promore Pharma in Media

Here we present media releases, interviews, images and videos.

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate of approximately 6 percent and is expected to reach USD 12 billion in 2024.